Literature DB >> 15302686

Coupling of the human A1 adenosine receptor to different heterotrimeric G proteins: evidence for agonist-specific G protein activation.

Yolande Cordeaux1, Adriaan P Ijzerman, Stephen J Hill.   

Abstract

The present study investigates the effect of varying ligand structure on the ability of agonists to activate guanine nucleotide-binding proteins of the Gi, Gs and Gq families via the A(1) adenosine receptor. In CHO cells expressing this receptor, inhibition or potentiation of forskolin-stimulated cAMP accumulation was used as an end point to measure the activation of Gi and, in Pertussis toxin (PTX)-treated cells, Gs, respectively. Stimulation of inositol phosphate accumulation in PTX-treated cells was used as an index of Gq activation. CPA (N(6)-cyclopentyladenosine), NECA (5'-N-ethyl-carboxyamidoadenosine) and eight analogues of these ligands presented a range of guanine nucleotide-binding protein (G-protein)-activating profiles. Some ligands could only activate Gi (e.g. 2'deoxyCPA), some primarily Gi and Gs (and only weakly Gq) (e.g. 3'deoxyCPA), highlighting the importance of the ribose hydroxyls in agonist activation of multiple G proteins. CHA (N(6)-cyclohexyladenosine) activated Gi, Gs and Gq, but was more efficacious than CPA in activating Gs. The NECA analogues 5'-N-cyclopropyl-carboxamidoadenosine, 5'-N-cyclobutyl-carboxamidoadenosine and 5'-N-cyclopentyl-carboxamidoadenosine (CPeCA) also activated all three G proteins, although their ability to activate Gs and Gq (relative to CPA) was reduced with increasing substituent size, such that CPeCA produced only a small stimulation (at 100 microM) at Gq, but was a full agonist, relative to CPA, at Gi and Gs. This study suggests that the A(1) adenosine receptor can adopt agonist-specific conformations, arising from small changes in ligand structure, which lead to the differential activation of Gi, Gs and Gq. British Journal of Pharmacology (2004).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15302686      PMCID: PMC1575922          DOI: 10.1038/sj.bjp.0705925

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  43 in total

Review 1.  Principles: extending the utility of [35S]GTP gamma S binding assays.

Authors:  Graeme Milligan
Journal:  Trends Pharmacol Sci       Date:  2003-02       Impact factor: 14.819

Review 2.  Agonist-receptor efficacy. II. Agonist trafficking of receptor signals.

Authors:  T Kenakin
Journal:  Trends Pharmacol Sci       Date:  1995-07       Impact factor: 14.819

3.  Agonist trafficking of G(i/o)-mediated alpha(2A)-adrenoceptor responses in HEL 92.1.7 cells.

Authors:  J P Kukkonen; C C Jansson; K E Akerman
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

4.  Influence of receptor number on functional responses elicited by agonists acting at the human adenosine A(1) receptor: evidence for signaling pathway-dependent changes in agonist potency and relative intrinsic activity.

Authors:  Y Cordeaux; S J Briddon; A E Megson; J McDonnell; J M Dickenson; S J Hill
Journal:  Mol Pharmacol       Date:  2000-11       Impact factor: 4.436

5.  Molecular analysis of beta(2)-adrenoceptor coupling to G(s)-, G(i)-, and G(q)-proteins.

Authors:  K Wenzel-Seifert; R Seifert
Journal:  Mol Pharmacol       Date:  2000-11       Impact factor: 4.436

6.  A1 adenosine receptors. Two amino acids are responsible for species differences in ligand recognition.

Authors:  A L Tucker; A S Robeva; H E Taylor; D Holeton; M Bockner; K R Lynch; J Linden
Journal:  J Biol Chem       Date:  1994-11-11       Impact factor: 5.157

7.  Differential involvement of intracellular domains of the rat NTS1 neurotensin receptor in coupling to G proteins: a molecular basis for agonist-directed trafficking of receptor stimulus.

Authors:  Delphine Skrzydelski; Anne-Marie Lhiaubet; Antony Lebeau; Patricia Forgez; Misa Yamada; Emmanuel Hermans; William Rostene; Didier Pelaprat
Journal:  Mol Pharmacol       Date:  2003-08       Impact factor: 4.436

8.  Characterization of a Ca2+ response to both UTP and ATP at human P2Y11 receptors: evidence for agonist-specific signaling.

Authors:  Pamela J White; Tania E Webb; Michael R Boarder
Journal:  Mol Pharmacol       Date:  2003-06       Impact factor: 4.436

9.  Identification of domains of the human A1 adenosine receptor that are important for binding receptor subtype-selective ligands using chimeric A1/A2a adenosine receptors.

Authors:  S A Rivkees; M E Lasbury; H Barbhaiya
Journal:  J Biol Chem       Date:  1995-09-01       Impact factor: 5.157

10.  Agonist-specific coupling of a cloned Drosophila octopamine/tyramine receptor to multiple second messenger systems.

Authors:  S Robb; T R Cheek; F L Hannan; L M Hall; J M Midgley; P D Evans
Journal:  EMBO J       Date:  1994-03-15       Impact factor: 11.598

View more
  37 in total

1.  Structural determinants in the second intracellular loop of the human cannabinoid CB1 receptor mediate selective coupling to G(s) and G(i).

Authors:  X P Chen; W Yang; Y Fan; J S Luo; K Hong; Z Wang; J F Yan; X Chen; J X Lu; J L Benovic; N M Zhou
Journal:  Br J Pharmacol       Date:  2010-12       Impact factor: 8.739

2.  The cannabinoid agonist WIN55,212-2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins.

Authors:  Jane E Lauckner; Bertil Hille; Ken Mackie
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-19       Impact factor: 11.205

3.  Internalization and desensitization of adenosine receptors.

Authors:  Elisabeth C Klaasse; Adriaan P Ijzerman; Willem J de Grip; Margot W Beukers
Journal:  Purinergic Signal       Date:  2007-11-13       Impact factor: 3.765

4.  Plasticity within striatal direct pathway neurons after neonatal dopamine depletion is mediated through a novel functional coupling of serotonin 5-HT2 receptors to the ERK 1/2 map kinase pathway.

Authors:  Pierre Brown; Charles R Gerfen
Journal:  J Comp Neurol       Date:  2006-09-20       Impact factor: 3.215

Review 5.  Allosteric modulation and functional selectivity of G protein-coupled receptors.

Authors:  Zhan-Guo Gao; Kenneth A Jacobson
Journal:  Drug Discov Today Technol       Date:  2013

Review 6.  A1 Adenosine Receptor Activation Modulates Central Nervous System Development and Repair.

Authors:  Shirin Kashfi; Kamran Ghaedi; Hossein Baharvand; Mohammad Hossein Nasr-Esfahani; Mohammad Javan
Journal:  Mol Neurobiol       Date:  2016-11-26       Impact factor: 5.590

7.  On the selectivity of the Gαq inhibitor UBO-QIC: A comparison with the Gαi inhibitor pertussis toxin.

Authors:  Zhan-Guo Gao; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2016-03-05       Impact factor: 5.858

8.  Noradrenaline stimulates cell proliferation by suppressing potassium channels via G(i/o) -protein-coupled α(1B) -adrenoceptors in human osteoblasts.

Authors:  D Kodama; A Togari
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

9.  Quantification of Gi-mediated inhibition of adenylyl cyclase activity reveals that UDP is a potent agonist of the human P2Y14 receptor.

Authors:  Rhonda L Carter; Ingrid P Fricks; Matthew O Barrett; Lauren E Burianek; Yixing Zhou; Hyojin Ko; Arijit Das; Kenneth A Jacobson; Eduardo R Lazarowski; T Kendall Harden
Journal:  Mol Pharmacol       Date:  2009-09-16       Impact factor: 4.436

10.  Influence of fluorophore and linker composition on the pharmacology of fluorescent adenosine A1 receptor ligands.

Authors:  Jillian G Baker; Richard Middleton; Luke Adams; Lauren T May; Stephen J Briddon; Barrie Kellam; Stephen J Hill
Journal:  Br J Pharmacol       Date:  2010-01-26       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.